Business
Two key patents granted in the US
Two key patents granted in the US.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n Verici Dx plc\n \n \n \n \n (\"Verici Dx\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Two key patents for Tutivia™ and Clarava™ granted in the United States \n \n \n \n \n Intellectual property portfolio strengthened\n \n \n \n \n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\n announces that it has been granted two key patents in the United States that support and protect the Company's core technologies in RNA signature biomarker tests used for assessment of\n the prognostic risk pre-transplant (\n Clarava™\n ) and post-transplant (\n Tutivia™\n ) of acute kidney transplant rejection.\n \n \n \n \n \n The patents cover broad molecular methods for predicting and diagnosing subclinical and clinical acute rejection, both pre- and post- kidney transplant by algorithmic analysis of gene sets and underpin both of Verici Dx's lead products, Tutivia™ and Clarava™, and provide protection until 2036 and 2039 respectively. The patents underpinning Tutivia™ have also been previously granted in Europe, China and Australia.\n \n \n \n \n \n These products use a weighted pattern of RNA biomarkers (signature) to assess the risk of rejection by the kidney transplant recipient and to assess rejection earlier and more reliably than other currently available methods. Verici Dx continues to file additional patents reflecting novel refinements to its predictive RNA signatures and methodologies driven by advanced machine learning techniques.\n \n \n \n \n \n The protection of the Company's intellectual property is fundamental to its strategy of amassing full transcriptomic data from the biological systems and interactions associated with transplant rejection and, over the longer term, informing transplant analysis in other organs and in the broader field of immune-mediated diseases.\n \n \n \n \n \n \n Sara Barrington, CEO of Verici Dx, said:\n \n \n \n \n \"\n \n \n Clarava™ and Tutivia™ address a significant unmet need and seek to improve\n \n \n outcomes for kidney transplant patients,\n \n \n by providing early, actionable information for clinicians to inform treatment plans. These significant new patents bolster our intellectual property portfolio and protect our proprietary methods of predicting and diagnosing sub-c...